Antibe Therapeutics Inc(Pre-Merger) ATBPF

There we are ...

[MrMugsy]

Finally - 6 months to the day ... roughly 180 days to close.
The CITA back-up plan is no more.
The final hurdle to co-listing is the price and don't look for anything short-term.
Won't be going until we're heading towards ~$6/share.

So ... just understand the stage is set.

-------------------------

Now - looking at the financials for Nov 14 - Nov 18.
Hoping for a more thorough update w.r.t IBD and the direction they are going with it.
IBD has been pushed out a few times and they are being hush-hush as to why.
I would assume 352 to be shelved (for now) as 346/IBD will be the focus and just maybe 352 becomes redundant with the improved 346 formulation.

346 Acute plan and figuring out the shortest path to 346 Chronic (P2 Confirmatory) will be top-of-mind in 2023.  IMO. 

Schmoozing Institutional Investors in 2023 is likely the key business initiative (now that CITA has been erased from any future plans - pure play drug developer).

-------------------------

Just wish we really understood what "significant dose reduction" meant and how it affects Acute and Chronic drug development.  Acute is easy to understand but how the dose reduction affects a Chronic plan is anyone's guess.  More of a 2023 thing anyway.

One step at a time. 

Good Luck !

[TriumphSpitSix]

"Just wish we really understood what "significant dose reduction" meant and how it affects Acute and Chronic drug development.  Acute is easy to understand but how the dose reduction affects a Chronic plan is anyone's guess." Not a doctor or chemist but from reading the NR, I believe it is primarily related to an increase in "bioavailability" i.e., how much

[Wriggles]

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry   Fully agree with that.  I would add that enhanced dissolution could possibly allow maintenance doses for chronic to be achieved with smaller but more frequent dosing.  Chronic is still a risk management issue IMO.   I think that

[MrMugsy]

A couple details I can add there folks ... The key to the improved formulation is in the crystalline structure of 346 - OR shall I say - the processing that reduces the crystalline structure in the new formulation.  That's the enhancement. Significant dose reduction (along with accelerated onset of action) is going to place Acute in the best place possible for us.  This is likely

[MrMugsy]

Question is ... we hit a hard limit on the lowest possible dose for chronic and that limit complicated what was possible.  Have we broken past that limit and can we go lower? I believe the answer is "yes" We don't know where this might take us and I'm thinking the details are in the animal studies - a good indication of what's possible with humans (it seems). Now - let